دورية أكاديمية
Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes
| العنوان: | Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes |
|---|---|
| المؤلفون: | Schmidt, Signe, Frandsen, Christian S., Dejgaard, Thomas F., Vistisen, Dorte, Halldórsson, Þórhallur Ingi, Olsen, Sjudur F., Jensen, Jens Erik B., Madsbad, Sten, Andersen, Henrik U., Nørgaard, Kirsten |
| المساهمون: | Faculty of Food Science and Nutrition |
| سنة النشر: | 2021 |
| المجموعة: | Opin vísindi (Iceland) |
| مصطلحات موضوعية: | Efnaskipti, Liraglútíð, Mataræði, Sykursýki, Líkamsþyngd, body composition, food frequency, insulin pump therapy, liraglutide, type 1 diabetes, weight loss, Internal Medicine, Endocrinology, Diabetes and Metabolism |
| الوصف: | Funding Information: We thank the participants and research team members Anette Hougaard and Merete Meldgaard Andersen for making this study possible. This study was supported by an unrestricted grant from Novo Nordisk A/S. The funder had no role in any part of this article. Funding Information: S.S. has served on an advisory panel for Medtronic and has received a research fellowship grant from the Danish Diabetes Academy supported by the Novo Nordisk Foundation. C.S.F. has received research support and lecture fees from Novo Nordisk. T.F.D. has served on advisory panels for Novo Nordisk, has received research support from Novo Nordisk and AstraZeneca and has received lecture fees from Novo Nordisk, AstraZeneca, Sanofi‐Aventis and Boehringer‐Ingelheim. D.V. is a shareholder in Novo Nordisk. J‐E.B.J. has served on advisory panels for Amgen, Eli Lilly, UCB Pharma, and Gedeon Richter, and has received lecture fees from Amgen, Eli Lilly, UCB Pharma, Gilead and Otsuka. S.M. has served on advisory panels for AstraZeneca, Boehringer‐Ingelheim, Eli Lilly, Merck Sharp & Dome, Novo Nordisk, Sanofi and Bayer, has received lecture fees from AstraZeneca, Boehringer‐Ingelheim, Merck Sharp & Dohme, Novo Nordisk and Sanofi, and has received research grants from Novo Nordisk and Boehringer‐Ingelheim. H.U.A. is a shareholder in Novo Nordisk, has served on advisory panels for Abbott, Novo Nordisk and AstraZeneca, and has received lecture fees from Nordic Infucare. K.N. is a shareholder in Novo Nordisk, has received research support from Novo Nordisk, Roche Diagnostics, Medtronic and Zealand Pharma, has received lecture fees from Medtronic, Roche Diagnostics, Rubin Medical, Sanofi, Zealand Pharma, Novo Nordisk and Dexcom, and has served on advisory panels for Medtronic, Abbott and Novo Nordisk. T.H. and S.F.O. have nothing to declare. Publisher Copyright: © 2021 John Wiley & Sons Ltd. ; Aims: To present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1462-8902 |
| العلاقة: | Diabetes, Obesity and Metabolism; (); http://www.scopus.com/inward/record.url?scp=85117111091&partnerID=8YFLogxKTest; Schmidt , S , Frandsen , C S , Dejgaard , T F , Vistisen , D , Halldórsson , Þ I , Olsen , S F , Jensen , J E B , Madsbad , S , Andersen , H U & Nørgaard , K 2021 , ' Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes ' , Diabetes, Obesity and Metabolism . https://doi.org/10.1111/dom.14567Test; a630a67d-0030-4c68-9750-74c8fb3e14ab; 85117111091; unpaywall: 10.1111/dom.14567; https://hdl.handle.net/20.500.11815/2810Test |
| DOI: | 10.1111/dom.14567 |
| الإتاحة: | https://doi.org/20.500.11815/2810Test https://doi.org/10.1111/dom.14567Test https://hdl.handle.net/20.500.11815/2810Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.41A2CE8A |
| قاعدة البيانات: | BASE |
| تدمد: | 14628902 |
|---|---|
| DOI: | 10.1111/dom.14567 |